Health Care • Biotechnology: Pharmaceutical Preparations
$36.91 ▼ -0.61
(-1.63%)
MKT CAP: $26.66B • VOL: 4.57M
52W L $19 52W H $43
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$31
MEDIAN
$41
MEAN
$42
HIGH
$50
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ROIV TAPE
ROIV // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $44.66 | $42.45 | 2025-02-14 | $33.59 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $46.51 | $43.55 | 2025-02-06 | $34.70 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $42.08 | $40.60 | 2025-01-29 | $35.43 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $37.65 | — | 2025-01-17 | $36.17 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $32.48 | $35.06 | 2025-01-09 | $32.85 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $43.92 | $38.39 | 2024-12-18 | $32.11 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $35.80 | $37.28 | 2024-12-04 | $34.33 | -4.3% | 48% | C |